Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.
(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...
Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui ...
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...
Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein (a), or Lp (a), ...
MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.
Merck inked a $2 billion licensing deal with China’s Hengrui Pharma for exclusive rights to an experimental heart disease ...
Key Takeaways The S&P 500 edged 0.2% higher on Tuesday, March 25, 2025, despite a report showing that consumer confidence ...
Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...
Big Pharma taps Chinese innovation again--this time for a potential blockbuster heart treatment targeting 1.4B people.
Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback